Intrafamilial Exposure to SARS-CoV-2 Induces Cellular Immune Response without Seroconversion

Study subjects

Seven households were enrolled in the study. Each involves at least one index patient with a documented proof of positive reverse-transcriptase polymerase chain reaction (RT-PCR) and /or serological testing for SARS-CoV-2, and at least one contact with a negative SARS-CoV-2 serology. All index patients recovered from a mild form of COVID-19 that occurred between March 2 and March 25, 2020. Clinical history was recorded for index patients and contacts. Blood samples for the present study were collected between May 7 and May 28, 2020. Ten healthy donors, who have not been exposed to COVID-19 patients and who have been tested negative for anti-SARS-CoV-2 antibodies, were enrolled as controls. All the participants gave written informed consent for research according to protocols approved by the institutional review board of Strasbourg University Hospitals (CE-2020-34).

SARS-CoV-2 RT-PCR and Serological tests

In house real-time reverse transcriptase PCR (RT-PCR) tests for SARS-CoV2 nucleic acid were performed on nasopharyngeal swabs. Primer and probe sequences target two regions on the RdRp gene and are specific to SARS-CoV2. Assay sensitivity is around 10 copies / reaction (Institut Pasteur, Paris, France). Three serological assays were used to determine the presence of anti-SARS-CoV-2 antibodies in index patients and contacts: i) The Abbott Architect SARS-CoV-2 IgG is a chemiluminescent microparticle immunoassay for detection of IgG against the SARS-CoV-2 nucleoprotein; and ii) The Euroimmun Anti-SARS-CoV-2 Assay is an enzyme-linked immunosorbent assay (ELISA) for the detection of IgG against the SARS-CoV-2 S1 domain of the spike protein including the immunologically relevant receptor binding domain (RBD). The two assays were approved by the FDA and the French National Agency of Medicine and Health Products Safety (ANSM) regarding their excellent analytical performances (Abbott Architect assay: sensitivity 100% and specificity 100% [9], and Euroimmun assay: sensitivity 100% and specificity 97.7%)[10]. iii) The Biosynex is a lateral flow assay for detection of IgM and IgG against the SARS-CoV-2 RBD of the Spike protein S. This assay was also approved by the ANSM with excellent analytical performances (specificity 99.4% and sensitivity 95.6% [11]). All of the three assays were tested according to manufacturer’s instructions.

IFN-1 Enzyme-linked Immunospot assay

T cell immune response against SARS-CoV-2 was investigated by performing an interferon-gamma (IFN-L) enzyme linked immunospot (ELISpot) assay in duplicate on fresh peripheral blood mononuclear cells (PBMCs) isolated from heparin-anticoagulated blood. PBMCs were seeded at 200,000 CD3 positive cells/well and stimulated for 20 +/- 4 hours with overlapping 15-mer peptide pools spanning the sequences of the entire SARS-CoV-2 spike glycoprotein (pools S1 and S2), the nucleoprotein (N), the membrane protein (M), the envelope small membrane protein (E) and the accessory proteins 3A, 7A, 8 and 9B (PepMix™, JPT Peptide Technologies, Strassberg, Germany). To investigate the possibility of pre-existing cross-reactive coronavirus-specific T cells, PBMCs were stimulated in parallel with peptide pools spanning the spike glycoprotein sequences of HCoV-229E (ES1 and ES2) and HCoV-OC43 (OS1 and OS2), respectively. Phytohemagglutinin (PHA) was used as a positive control and culture medium in quadruplicate as a negative control. After colorimetric revelation of IFNγ capture (UCytech, Utrecht, The Netherlands), spots were counted using an ELISPOT reader (AID, Strassberg, Germany). For each condition, the mean number of spot forming cells per million CD3 positive cells was calculated from duplicates after subtraction of the background value obtained from negative controls to determine the frequency of antigen specific T cells. The threshold defining a significant SARS-CoV-2-specific response was set at exceeding 3 standard deviations of the negative control background.

Index patients and contacts characteristics

Nine index patients (P1, P2, P3A, P3B, P3C, P4, P5, P6 and P7) recovered from a mild COVID-19 with positive serological testing for SARS-CoV-2 and eight contacts (C1, C2, C3, C4A, C4B, C5, C6 and C7) with negative serological testing for SARS-CoV-2 were enrolled in the study. For each household, blood samples were collected the same day, except for the household 5 (Table 1). The median age of index patients was 45 years (range, 34-65 years) and four (50%) were male. They all had a normal lymphocyte count (table 1). SARS-CoV-2 RT-PCR test was performed for 4 households (4, 5, 6 and 7) in nasopharyngeal specimens. RT-PCR was positive for all the index patients and negative for all the contacts (Table 1). Of the nine index patients, five were healthcare workers and two of them reported a history of contacts with COVID-19 positive patients during their work. Patients reported history of fever (n=5), cough (n=6), headache (n=6), anosmia (n=7), ageusia (n=6), and less often dyspnea (n=2) and myalgia (n=2). The duration of symptoms varied from 2 to 15 days (median 7 days). All families rigorously washed their hands and all except one family (Household 2) avoided hugs and kisses with household members. Only two index patients (P4 and P6) quarantined themselves by dieting separately and/or wearing a mask one and three days after symptom onset, respectively. Of the eight contacts, two (C3 and C6) had no symptoms, four had fever, three had cough, four had headache and one had ageusia. The duration of symptoms varied from 1 to 11 days (median 7 days) (Table 1).

Serological status for SARS-CoV-2 was confirmed for index patients and contacts by using three different serological assays (Table 1). To determine whether SARS-CoV-2 specific T cells were induced in index patients and contacts, fresh PBMC samples were stimulated with structural and accessory SARS-CoV-2 proteins followed by IFNγ ELISPOT analysis. All index patients showed SARS-CoV-2-specific IFNγ responses against at least four SARS-CoV-2 antigens with a maximum of eight antigens. They all recognized the structural proteins S1, S2, N and M, and six of them recognized at least one accessory protein (3A and/or 7A, 8, 9B), suggesting that they had developed SARS-CoV-2-specific T cell responses (Fig.1A and 2). Importantly, blood samples were collected from 47 to 69 days post symptom onset, which suggests that antiviral T cells are maintained in patients recovered from a mild COVID-19 up to 69 days post symptoms.

• Download figure
• Open in new tab

Figure 1. Frequency of IFN-⍰ spot forming cells against SARS-CoV-2 and two common human coronaviruses antigens in index patients, contacts and unexposed healthy donors.

Means of spot counts of IFN-⍰ T cell response per million of CD3 are indicated. The experiments were performed in duplicates. T-cell secretion of IFN-⍰ was determined against (A) the SARS-CoV-2 structural proteins S1, S2, N, M and the accessory proteins 3A, 7A, 8 and 9B and against (B) the structural proteins of the human coronaviruses HCoV-229E (ES1, ES2) and HCoV-OC43 (OS1, OS2). Each color correspond to one antigen. P, index patient; C, contact; HD, unexposed healthy donor.

• Download figure
• Open in new tab

Figure 2. SARS-CoV-2-specific T cell response pattern in households.

Means of spot counts of IFN-⍰ T cell response per million of CD3 against SARS-CoV-2 antigens in each household are shown. The X axis represent the SARS-CoV-2 antigens. The experiments were performed in duplicates. White and grey bars correspond to T cell responses detected in index patients and black bars correspond to those detected in contacts. P, index patient, C, contact.

Six of eight contacts demonstrated SARS-CoV-2 –specific IFNγ responses against at least one SARS-CoV-2 antigen (Fig.1A and 2). The contacts C1 and C4A exhibited a T-cell reactivity against five SARS-CoV-2 antigens including two structural proteins and three accessory proteins; the contact C5 exhibited a T-cell reactivity against the two structural proteins N and E and the accessory protein 9B; the contacts C2, C6 and C7 exhibited a T-cell reactivity against S2, 8/9B and S1, respectively. Of note, the frequencies of IFNγ-secreting T cells in contacts C1, C2, C4A, C5 and C7 were similar to those displayed by the index patients and much higher than those detected in unexposed healthy donors (HD) except for the antigen S2 for which HD10 displayed a similar frequency as for index patients and contacts (Fig. 1A and 2). This suggests that the contacts had developed SARS-CoV-2-specific T cell responses.

We tested index patients, contacts and unexposed healthy donors for the spike protein (pools S1 and S2) of HCoV-229E and HCoV-OC43. They all but one unexposed healthy donor (HD9) showed a high frequency of IFNγ-producing T cells directed against HCoV 229E and/or HCoV OC43 (Figure 1B).